查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008084

丛状神经纤维瘤治疗市场：依药物类别、患者群、通路和地区划分

Plexiform Neurofibromas Treatment Market, By Drug Class, By Patient Population, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2026年，神经丛神经纤维瘤治疗市场规模估计为18.88亿美元，预计2033年将达到32.65亿美元。预计从2026年到2033年，该市场将以8.4%的复合年增长率成长。

分析范围 分析详情
基准年 2025 市场规模（2026 年） 18.88亿美元
效能数据 2020-2024 预测期 2026-2033
预测期（2026-2033 年）复合年增长率 8.40% 预计金额（2033 年） 32.65亿美元

丛状神经纤维瘤是第一型神经纤维瘤的一种罕见亚型，表现为隆起、畸形的肿块，起源于多条神经，并延伸至结缔组织和皮肤褶皱处。神经纤维瘤是一种遗传性神经系统疾病，可涉及皮肤、神经、脑部和脊髓。神经纤维瘤（或称为肿瘤）可沿着体内神经生长，也可生长于皮肤表面或皮下。神经纤维瘤分为三种类型，每种类型都有其特定的症状和体征：1型神经纤维瘤（NF1）、2型神经纤维瘤（NF2）和雪旺氏细胞瘤病。丛状神经纤维瘤是第1型神经纤维瘤（NF1）的一种病理特异性观察，也是神经纤维瘤的常见併发症。丛状神经纤维瘤主要为遗传性肿瘤，可发生于身体任何部位，包括头颈部、四肢、脊椎周围以及体内深处，并可能涉及器官。丛状神经纤维瘤通常在婴儿期确诊，约30%的NF1患者会出现这种肿瘤。丛状神经纤维瘤范围广泛，涉及长神经纤维及其分支，并且常常突破神经膜，并侵入周围组织。

市场动态

预计在预测期内，采用有机成长策略，例如获得美国食品药物管理局(FDA) 等监管机构的产品核可，将推动全球神经丛神经纤维瘤治疗市场的成长。例如，2020 年 4 月，生物製药公司Astra Zeneca宣布，其药物Selumetinib （商品名为「Koselugo」）已获得美国食品药物管理局(FDA) 的核准，用于治疗 2 岁及以上儿童的1 型神经纤维瘤病。 Selumetinib 是一种激酶抑制剂，也是第一个核准用于治疗方法儿童神经纤维瘤的药物。

本报告的主要特点

  • 本报告指出了各个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
  • 此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
  • 本节根据以下参数介绍全球神经丛神经纤维瘤治疗市场中主要企业的概况：公司概况、产品系列、主要亮点、财务表现和策略。
  • 本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
  • 《全球丛状神经纤维瘤治疗市场》报告面向该行业的各种相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 相关人员可以透过分析全球神经丛神经纤维瘤治疗市场中使用的各种策略矩阵来促进决策。

目录

第一章：分析目标与假设

  • 分析目的
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章：市场动态、监管与趋势分析

  • 市场动态
    • 促进因素
    • 抑制因子
    • 市场机会
  • 影响分析
  • 市场趋势
  • PEST分析
  • 波特五力分析
  • 主要进展
  • 品牌分析
  • 企业合併和商业联盟的趋势
  • 流行病学
  • 产品核准和发布
  • 治疗流程
  • 治疗方案分析
  • 作用部位（作用机转）
  • 主要企业的新投资
  • 製造商销售
  • 疾病意识计划
  • 各国医疗费用支出

第四章：全球丛状神经纤维瘤治疗市场：依药物类别划分（2020-2033 年）

  • 概述
  • Selumetinib
  • 非类固醇消炎剂（NSAIDs）
  • 抗惊厥药物
  • 其他（例如，三环抗忧郁药物）

第五章：全球神经纤维瘤治疗市场：依病患群体划分（2020-2033 年）

  • 概述
  • 儿童
  • 成人

第六章：全球丛状神经纤维瘤治疗市场：依通路划分（2020-2033 年）

  • 概述
  • 医院药房
  • 零售药房
  • 网路药房

第七章 全球丛状神经纤维瘤治疗市场：按地区划分（2020-2033 年）

  • 北美洲
    • 我们
  • 加拿大
  • 拉丁美洲
    • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 欧洲
    • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
    • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 中东
    • GCC
  • 以色列
  • 其他中东国家
  • 非洲
    • 北非
  • 中非
  • 南非

第八章 竞争情势

  • AstraZeneca
  • Pfizer Inc.
  • Sun Pharmaceuticals Industries Limited
  • Mallinckrodt Pharmaceuticals
  • SpringWorks Therapeutics
  • Alcaliber SA
  • Teva Pharmaceutical Industries Ltd.
  • Glenmark
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma
  • Apotex Inc.
  • Mylan NV
  • GSK plc.
  • Solara Active Pharma Sciences Ltd.
  • Abbott
  • Shanghai Kechow Pharma, Inc.
  • Endo Pharmaceuticals Inc.
  • Purdue Pharma LP
  • Merck &Co., Inc.
  • NFlection Therapeutics
  • Healx
  • Array Biopharma

第九章

  • 分析方法
  • 关于 Coherent Market Insights
简介目录
Product Code: CMI5430

Plexiform Neurofibromas Treatment Market is estimated to be valued at USD 1,888.0 Mn in 2026 and is expected to reach USD 3,265.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.4% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 1,888.0 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 8.40% 2033 Value Projection: USD 3,265.0 Mn

Plexiform neurofibromas is an uncommon variant of neurofibromatosis type 1 that arises from multiple nerves as bulging and deforming masses involving also connective tissue and skin folds. Neurofibromatosis is a genetic neurological disorder which can affect the skin, nerves, brain, and spinal cord. Neurofibromas or tumors, grow along the body's nerves or on or underneath the skin. There are three types of neurofibromatosis that are associated with unique symptoms and signs, Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2), and Schwannomatosis. Plexiform neurofibromas are essentially pathognomonic of neurofibromatosis type 1 (NF1) which is a common complication of neurofibromatosis. Plexiform neurofibromas are predominantly inherited tumors that can occur anywhere in the body. This includes the head and neck, extremities, areas around the spine and deep in the body where they may affect organs. Plexiform neurofibromas are usually diagnosed in early childhood. They are found in approximately 30% of patients with NF1. Plexiform neurofibromas diffusely involve long nerve segments and its branches, often extending beyond the epineurium into the surrounding tissue.

Market Dynamics

Adoption of inorganic strategies, such as product approval, by regulatory authority such as the U.S. Food and Drug Administration is expected to drive the global plexiform neurofibromas treatment market growth over the forecast period. For instance, in April 2020, AstraZeneca, a biopharmaceutical company, announced that they had received an approval from the U.S. Food and Drug Administration for Selumetinib under the brand name Koselugo, for pediatric patients, 2 years of age and older, with neurofibromatosis type 1. Selumetinib is a kinase inhibitor and the first therapy approved for pediatric patients with neurofibromatosis.

Key features of the study

  • This report provides an in-depth analysis of the global plexiform neurofibromas treatment market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global plexiform neurofibromas treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include AstraZeneca, Pfizer Inc., Sun Pharmaceuticals Industries Limited, Mallinckrodt Pharmaceuticals, SpringWorks Therapeutics, Alcaliber S.A, Teva Pharmaceutical Industries Ltd., Glenmark, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Apotex Inc., Mylan N.V., GSK plc., Solara Active Pharma Sciences Ltd., Abbott, Shanghai Kechow Pharma, Inc., Endo Pharmaceuticals Inc., Purdue Pharma L.P, Merck & Co., Inc., NFlection Therapeutics, Healx, and Array Biopharma
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global plexiform neurofibromas treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plexiform neurofibromas treatment market

Market Segmentation

  • By Drug Class (Revenue, USD Mn, 2020 - 2033)
    • Selumetinib
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Anticonvulsants
    • Others (Tricyclic Antidepressants, etc.)
  • By Application Insights (Revenue, USD Mn, 2020 - 2033)
    • Pediatric
    • Adult
  • By End User Insights (Revenue, USD Mn, 2020 - 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region Insights (Revenue, USD Mn, 2020 - 2033)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East & Africa
    • GCC Countries
    • Israel
    • Rest of Middle East & Africa
  • Key Players
    • AstraZeneca
    • Pfizer Inc.
    • Sun Pharmaceuticals Industries Limited
    • Mallinckrodt Pharmaceuticals
    • SpringWorks Therapeutics
    • Alcaliber S.A
    • Teva Pharmaceutical Industries Ltd.
    • Glenmark, Amneal Pharmaceuticals LLC
    • Aurobindo Pharma
    • Apotex Inc.
    • Mylan N.V.
    • GSK plc.
    • Solara Active Pharma Sciences Ltd.
    • Abbott
    • Shanghai Kechow Pharma, Inc.
    • Endo Pharmaceuticals Inc.
    • Purdue Pharma L.P.
    • Merck & Co., Inc.
    • NFlection Therapeutics
    • Healx
    • Array Biopharma

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Patient Population
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • PEST Analysis
  • PORTER's Analysis
  • Key Developments
  • Brand Analysis
  • Merger and Collaboration Scenario
  • Epidemiology
  • Product Approvals/Launches
  • Treatment Algorithm
  • Treatment Option Analysis
  • Site of Activity (Mode of Action)
  • New Investments by Major Market Players
  • Manufacturer Revenue
  • Disease Awareness Programs
  • Healthcare Spending by Country

4. Global Plexiform Neurofibromas Treatment Market, By Drug Class, 2020-2033, (USD Mn)

  • Overview
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2020-2033
    • Segment Trends
  • Selumetinib
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Anticonvulsants
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Others (Tricyclic Antidepressants, etc.)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

5. Global Plexiform Neurofibromas Treatment Market, By Patient Population, 2020-2033, (USD Mn)

  • Overview
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2020-2033
    • Segment Trends
  • Pediatric
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Adult
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

6. Global Plexiform Neurofibromas Treatment Market, By Distribution Channel, 2020-2033, (USD Mn)

  • Overview
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2020-2033
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

7. Global Plexiform Neurofibromas Treatment Market, By Region, 2020-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, For Regions, 2020-2033
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
      • U.S.
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Canada
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
      • Brazil
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Mexico
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Argentina
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Rest of Latin America
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
      • U.K.
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Germany
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Italy
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • France
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Spain
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Russia
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Rest of Europe
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
      • China
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • India
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Japan
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • ASEAN
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Australia
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • South Korea
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Rest of Asia Pacific
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
      • GCC
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Israel
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Rest of Middle East
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2033, (USD Mn)
      • North Africa
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Central Africa
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • South Africa
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)

8. Competitive Landscape

  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sun Pharmaceuticals Industries Limited
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mallinckrodt Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • SpringWorks Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Alcaliber S.A
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Glenmark
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Amneal Pharmaceuticals LLC
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Aurobindo Pharma
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Apotex Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GSK plc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Solara Active Pharma Sciences Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Abbott
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Shanghai Kechow Pharma, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Endo Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Purdue Pharma L.P
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • NFlection Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Healx
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Array Biopharma
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

9. Section

  • Research Methodology
  • About Us